Filing Details
- Accession Number:
- 0001415889-24-025436
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-18 18:51:26
- Reporting Period:
- 2024-10-16
- Accepted Time:
- 2024-10-18 18:51:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1817713 | Janux Therapeutics Inc. | JANX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1376355 | Jay Lichter | 11099 N Torrey Pines Road, Suite 290 La Jolla CA 92037 | No | No | Yes | No | |
| 1652901 | Avalon Ventures Xi, L.p. | 1134 Kline Street La Jolla CA 92037 | No | No | No | No | |
| 1844550 | Avalon Bioventures Spv I, L.p. | 11099 N Torrey Pines Road, Suite 290 La Jolla CA 92037 | No | No | Yes | No | |
| 1873935 | Avalon Bioventures I, Lp | 11099 N Torrey Pines Road, Suite 290 La Jolla CA 92037 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-10-16 | 60,179 | $49.69 | 2,761,291 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-16 | 11,657 | $49.69 | 534,883 | No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| Common Stock | Disposition | 2024-10-16 | 61,445 | $49.69 | 2,819,366 | No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
| Common Stock | Disposition | 2024-10-16 | 29,474 | $50.61 | 2,731,817 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-16 | 5,710 | $50.61 | 529,173 | No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| Common Stock | Disposition | 2024-10-16 | 30,094 | $50.61 | 2,789,272 | No | 4 | S | Indirect | By Avalon BioVentures SPV I, LP |
| Common Stock | Acquisiton | 2024-10-16 | 4,968 | $17.00 | 11,855 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-16 | 2,070 | $10.73 | 13,925 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-16 | 2,070 | $13.22 | 15,995 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-16 | 1,407 | $39.80 | 17,402 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-10-16 | 10,957 | $50.80 | 6,445 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-10-17 | 836 | $17.00 | 7,281 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-17 | 348 | $10.73 | 7,629 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-17 | 348 | $13.22 | 7,977 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-10-17 | 237 | $39.80 | 8,214 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-10-17 | 1,843 | $50.02 | 6,371 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-18 | 102,732 | $50.30 | 2,629,085 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-18 | 19,900 | $50.30 | 509,273 | No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| Common Stock | Disposition | 2024-10-18 | 104,892 | $50.30 | 2,684,380 | No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
| Common Stock | Disposition | 2024-10-18 | 15,462 | $51.18 | 2,613,623 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-18 | 2,995 | $51.18 | 506,278 | No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| Common Stock | Disposition | 2024-10-18 | 15,788 | $51.18 | 2,668,592 | No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
| Common Stock | Disposition | 2024-10-18 | 541,824 | $44.75 | 2,071,799 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-18 | 104,957 | $44.75 | 401,321 | No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| Common Stock | Disposition | 2024-10-18 | 553,219 | $44.75 | 2,115,373 | No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| No | 4 | S | Indirect | By Avalon BioVentures SPV I, LP |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | By Avalon BioVentures I, LP |
| No | 4 | S | Indirect | By Avalon BioVentures SPV I, L.P. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-16 | 4,968 | $0.00 | 4,968 | $17.00 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-16 | 2,070 | $0.00 | 2,070 | $10.73 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-16 | 2,070 | $0.00 | 2,070 | $13.22 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-16 | 1,407 | $0.00 | 1,407 | $39.80 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-17 | 836 | $0.00 | 836 | $17.00 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-17 | 348 | $0.00 | 348 | $10.73 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-17 | 348 | $0.00 | 348 | $13.22 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-10-17 | 237 | $0.00 | 237 | $39.80 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 22,776 | 2027-07-19 | No | 4 | M | Direct | |
| 9,490 | 2027-07-19 | No | 4 | M | Direct | |
| 9,490 | 2027-07-19 | No | 4 | M | Direct | |
| 6,309 | 2027-07-19 | No | 4 | M | Direct | |
| 21,940 | 2027-07-19 | No | 4 | M | Direct | |
| 9,142 | 2027-07-19 | No | 4 | M | Direct | |
| 9,142 | 2027-07-19 | No | 4 | M | Direct | |
| 6,072 | 2027-07-19 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- The securities are directly held by Mr. Lichter.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.76 to $51.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024.
- Immediately exercisable.
Billionaire Hedge Funds
